- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01393704
Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial
The main purpose of this study is to compare blood loss at the time of laparoscopic or robotically-assisted laparoscopic myomectomy when using different amounts of dilute vasopressin solution. Myomectomy is a surgical procedure to remove fibroids from the uterus. Vasopressin is a synthetic drug used to help decrease blood loss at the time of gynecologic surgery; although very little is know about the optimal dosage and administration.
The investigators plan to perform a randomized clinical trial on patients scheduled for minimally invasive myomectomy. All patients will get the same overall amount of vasopressin. Patients will be assigned by chance to one of two groups: one group will receive higher volume of a more dilute vasopressin solution. The other group will receive a lower volume of a more concentrated solution. The investigators will collect information on operative blood loss and complications related to surgery.
Study Overview
Detailed Description
All surgeons who enroll patients into our study are experienced laparoscopic surgeons who have performed at least 100 advanced laparoscopic procedures including hysterectomies and myomectomies. Briefly, our laparoscopic myomectomy technique is as follows: After gaining peritoneal access and placing visual and operative trocars, the surgical site is inspected carefully and fibroid locations identified. After informing the anesthesia team that vasopressin (from pharmaceutical company American Regent 20 units/ml) is about to be injected, the uterus is infiltrated with vasopressin.
Patients will be randomized one of two treatment groups pre-operatively on the day of surgery:
- One arm will receive injection of 200 ml total of the 0.05 units/ml dilute vasopressin solution (total 10 units Vasopressin used, dilution of 20 units vasopressin in 400 ml of normal saline).
- The second arm will receive injection of 30 ml total of the 0.3 units/ml dilute vasopressin solution (total 10 units Vasopressin used, dilution of 20 units Vasopressin in 60 mL of Normal Saline).
The procedure is done according to surgeon preference using various energy modalities such as monopolar or Harmonic Scalpel® (Ethicon Endo-Surgery, Cincinnati OH), for making the incision in the uterus. The fibroid is then removed from the uterus and examined. The incision is then closed in several layers with laparoscopic standard suturing technique, and hysterotomy site is generally covered with an adhesion barrier (Gynecare Interceed® (Ethicon Women's Health and Urology, Somerville NJ) or Seprafilm® slurry (Genzyme Biosurgery, Framingham MA)).
Blood Samples:
As per routine, preoperative blood samples to assess hematocrit levels will be taken no greater than 2 weeks prior to surgical date; if no preoperative laboratory studies have been obtained a sample will be drawn on the day of surgery. Postoperative blood samples to assess hematocrit will be taken no sooner than 4 hours after surgery for patients who are discharged the same day; for patients who are monitored overnight in hospital, the lab will be drawn on postoperative day #1.
Follow-up:
Patients will be followed for 8 weeks after surgery to assess for occurrence of any postoperative complication. A member of the team (health care worker such as research assistant who has been trained in HIPPA procedures) will be in charge of abstracting data from the medical records and entering this information into a study database.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham&Women's hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The inclusion criteria for our study include all women who are candidates for a laparoscopic or robotic-assisted laparoscopic myomectomy and are willing to accept randomization.
- The exclusion criteria: for our study include: suspected malignancy or contraindication to morcellation of uterine tissue, history of adverse reaction or allergy to vasopressin, and active cardiovascular or pulmonary disease that would indicate a contradiction to use of vasopressin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: High Volume Dilute Vasopressin
20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
|
Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
Other Names:
|
Active Comparator: Low volume dilute vasopressin
20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
|
Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimating Blood Loss at the End of Myomectomy - Hematocrit Percentage
Time Frame: 5 minutes post-operatively
|
To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome.
Pre and post-operative hematocrit change (%) was one of these measurement methods.
|
5 minutes post-operatively
|
Estimating Blood Loss at the End of Myomectomy - Surgeon Estimated Blood Loss
Time Frame: 5 minutes post-operatively
|
To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome: Subjective surgeon's estimate of blood loss (ml) was one measurement method.
|
5 minutes post-operatively
|
Estimating Blood Loss at the End of Myomectomy - Suction Canister Estimated Blood Loss Calculation
Time Frame: 5 minutes post-operatively
|
To evaluate whether volume of dilute Vasopressin administered during minimally-invasive myomectomy affects blood loss, three parameters will be collected to assess this outcome.
Objective calculation of blood loss via the measurement of suction canister fluid (ml) was one of these.
The calculation for estimated blood loss will be as follows: EBL = [total suction canister volume] - [volume of irrigation used] - [volume of vasopressin solution injected /2].
|
5 minutes post-operatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Peri-operative Complications
Time Frame: 8 weeks postoperatively
|
Intra or post-operative complications (including but not limited to need for blood transfusion or adverse effect related to Vasopressin).
|
8 weeks postoperatively
|
Total Operation Time
Time Frame: 5 minutes postoperatively
|
Time from incision to end of surgery
|
5 minutes postoperatively
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jon I Einarsson, MD,MPH., Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-P-000264/1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Loss, Surgical
-
The University of Texas Health Science Center at...RecruitingMyomectomy; Surgical Blood LossUnited States
-
Assiut UniversityCompletedHepatectomy, Surgical Blood Loss, TerlipressinEgypt
-
Northwell HealthCompletedSurgical Blood LossUnited States
-
i-SEPCompletedHemorrhage | Blood Loss | Surgical Blood LossFrance
-
CSL BehringCompletedSurgical Blood Loss | Postoperative Blood LossUnited Kingdom, Canada, Japan, Italy, Poland, Germany, Czech Republic, Austria, Brazil, Denmark, Finland
-
Cubist Pharmaceuticals LLCCompletedSurgical Procedures, Operative | BloodlossGermany, Poland, United States
-
Cubist Pharmaceuticals LLCCompletedSurgical Procedures, Operative | BloodlossUnited States, Canada
-
University Health Network, TorontoThe Physicians' Services Incorporated FoundationCompletedTotal Knee Arthroplasty | Surgical Blood LossCanada
-
Population Health Research InstituteCompletedBleeding | Surgical Blood LossCanada
-
Australian and New Zealand Intensive Care Research...Australian Red CrossActive, not recruiting
Clinical Trials on Vasopressin
-
Seoul National University HospitalCHA UniversityCompletedComparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy (VALENTINE)Uterine LeiomyomaKorea, Republic of
-
Columbia UniversityCompletedHypertension | End Stage Renal DiseaseUnited States
-
Intermountain Health Care, Inc.University of UtahEnrolling by invitation
-
Osaka UniversityOsaka City UniversityCompleted
-
Hangang Sacred Heart HospitalAsan Medical CenterUnknownBurn SurgeryKorea, Republic of
-
University Hospitals Cleveland Medical CenterWithdrawn
-
Ascher-Walsh, Charles, M.D.CompletedBlood Loss During Vaginal HysterectomyUnited States
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
University of Maryland, BaltimoreRecruiting
-
Stanford UniversityCompletedHypotension | Fontan PhysiologyUnited States